Actualités sur Krankheit

TES Pharma

TES Pharma Congratulates Intercept Pharmaceuticals on their Presentation of Phase 1 INT-787 Data at the AASLD Meeting and the Initiation of the Phase 2a FRESH Study in Patients with Severe Alcohol-Associated Hepatitis

Perugia, Italy (ots/PRNewswire) - INT-787 is a selective next generation FXR agonist invented by TES Pharma and licensed to Intercept Pharmaceuticals INT-787 has shown strong anti-fibrotic and anti-inflammatory effects in animal models TES Pharma is dedicated to the identification of novel therapeutic targets and ...

McGill University

Forging a healthier future through research: McGill University launches new Institute of Genomic Medicine

Montreal (ots/PRNewswire) - Landmark donation from alumnus Dr. Victor Phillip Dahdaleh will accelerate advances in global health using genomic medicine to inform patient diagnosis and care A landmark donation to support McGill University's renowned genomics research and education programs from UK-based alumnus and ...

The International Osteoporosis Foundation (IOF)

On World Osteoporosis Day, take five steps to better bone health

Menarini-Silicon Biosystems

Menarini Silicon Biosystems's CELLSEARCH® CMMC and HER2-CTC Liquid Biopsy Tests obtain Reimbursement Codes with Preliminary Pricing Determination

Huntingdon Valley, Pa. (ots/PRNewswire) - These new codes are required to access Medicare/Medicaid insurance reimbursement for novel CELLSEARCH Circulating Multiple Myeloma Cell (CMMC) and HER2 Circulating Tumor Cell (CTC-HER2) assays, to monitor disease status in patients with life-threatening illnesses. Menarini ...

Pharming Group N.V.

Pharming submits a Marketing Authorisation Application to the European Medicines Agency for Leniolisib

Leiden, Netherlands (ots/PRNewswire) - Application is based on randomized, controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency This submission follows the grant of accelerated assessment allowing an expedited review for leniolisib from a standard 210 days ...

Evonik Industries AG

Evonik and Phathom Pharmaceuticals partner to produce novel acid-blocker vonoprazan

Essen, Germany (ots/PRNewswire) - - Evonik to produce commercial quantities of the drug substance vonoprazan for use in VOQUEZNA™ TRIPLE PAK™ and DUAL PAK™, and other products containing vonoprazan - Supply security through production at sites in Europe and North America - Agreement strengthens Evonik's track record as leading contract development and ...

Servier

Servier unveils its 2030 ambition and reveals a new visual identity

Paris (ots/PRNewswire) - - A new ambition by 2030 to accelerate its transformation dynamic - A visual identity, a marker of the successful transformation of the Group, its ambitions and its renewal Servier today unveils its 2030 ambition as well as a new visual identity that reflects the transformation undertaken by the Group, bringing visible results. The Group intends to accelerate its transformation dynamics in order ...

Debiopharm International SA

DEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY

Lausanne, Switzerland (ots) - Debiopharm awards the winning scientists for the JCA (Japanese Cancer Association) Award for innovative, disruptive, and translational oncology research Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of JCA Mauvernay ...

PHARMANOVIA

PHARMANOVIA ENTERS EXCLUSIVE LICENSING COLLABORATION FOR DIAZEPAM BUCCAL FILM

London (ots/PRNewswire) - - PHARMANOVIA EXCLUSIVELY LICENCES RIGHTS FOR A NOVEL WAY OF TREATING ACUTE EPILEPSY SEIZURE CLUSTERS IN EUROPE, MIDDLE EAST AND NORTH AFRICA - PATENTED BUCCAL FILM TECHNOLOGY HAS THE POTENTIAL TO IMPROVE THE EASE OF ADMINISTRATION FOR CAREGIVERS, PATIENTS AND HCPs Pharmanovia, the lifecycle management company, has today announced that it has ...

MC2 Therapeutics

MC2 Therapeutics announces initiation of a Phase 2 clinical trial in CKD-aP

Copenhagen, Denmark (ots/PRNewswire) - - Trial based on the recent breakthrough discovery of a novel treatment paradigm for urea associated skin diseases - First patients dosed in Europe in Phase 2 trial assessing the safety and efficacy of MC2-25 Cream in Chronic Kidney Disease-associated Pruritus (CKD-aP) stages 3-5 patients - MC2-25 Cream has the potential to become ...

MC2 Therapeutics

MC2 Therapeutics announces initiation of a Phase 2 clinical trial in CKD-aP

Copenhagen, Denmark (ots/PRNewswire) - - Trial based on the recent breakthrough discovery of a novel treatment paradigm for urea associated skin diseases - First patients dosed in Europe in Phase 2 trial assessing the safety and efficacy of MC2-25 Cream in Chronic Kidney Disease-associated Pruritus (CKD-aP) stages 3-5 patients - MC2-25 Cream has the potential to become ...

European Society for Medical Oncology (ESMO)

ESMO 2022 - Great oaks grow from small acorns: oncology is committed to doing its part for sustainability

Paris (ots) - At ESMO 2022, 9-13 September, Paris, France, the premier cancer congress in Europe, which has gathered 28k participants from 167 countries, many discussions will be around sustainability, prevention and novel approaches which could soon become a reality in the clinic. - Late-breaking results elucidate ...

Almirall, S.A.

Almirall: Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Phase 3 Monotherapy Atopic Dermatitis Trials

Barcelona, Spain (ots/PRNewswire) - - New, late-breaking data show lebrikizumab responders reported long-lasting results at one year of treatment across measures of improvement in skin clearance, itch and disease extent and severity - Results suggest less frequent, every four week dosing of lebrikizumab provided ...

Debiopharm International SA

ONE DRUG FOR ONE BUG: DEBIOPHARM TO DISCUSS THE POTENTIAL OF PATHOGEN-SPECIFIC ANTIBIOTICS AT THE 2022 WORLD AMR CONGRESS

Lausanne, Switzerland (ots) - - International health authorities, such as the WHO and the CDC are warning of the emerging danger of bacterial infections resistant to current antibiotics - The 2022 World Anti-Microbial Resistance (AMR) Congress in the greater Washington D.C. area is serving as a forum to openly ...

Schweizerischer Nationalfonds / Fonds national suisse

Broad-based Swiss Covid-19 research

Bern (ots) - During the coronavirus pandemic, the Swiss National Science Foundation (SNSF) supported a total of 114 Covid-19 research projects, for which it used funding of over CHF 45 million. In the National Research Programme "Covid-19" (NRP 78), around 200 researchers are working in 28 projects with a total budget of CHF 20 million. Another research programme on Covid-19 is about to start. It was the first time the ...

Medison Pharma

Medison Pharma Announces the Expansion of its Partnership with Albireo to a Multi-Regional Agreement to Commercialize Odevixibat in Canada and Israel

Petach Tikvah, Israel (ots/PRNewswire) - Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, announced today the expansion of its partnership with Albireo to a multi-regional agreement to commercialize Odevixibat in ...

The Global Fund

Catalytic Investment to Improve Community Health Care for Millions Across Africa

Geneva (ots/PRNewswire) - The Global Fund collaborates with the Johnson & Johnson Foundation and the Skoll Foundation to Launch the Africa Frontline First Catalytic Fund - Private sector investments to the Global Fund's Africa Frontline First Catalytic Fund from the Johnson & Johnson Foundation and the Skoll Foundation totaling US$ 25 million. - The Global Fund to ...

The Global Fund

Global Fund Reports Significant Progress in Breaking Down Human Rights-Related Barriers to HIV and TB Services

Montreal (ots/PRNewswire) - A new report released by the Global Fund today at the 24th International AIDS Conference unveils key findings of the activities supported by the Global Fund's Breaking Down Barriers initiative, a groundbreaking program launched in 2017 to provide intensive financial and technical support ...

Grünenthal Group

Grünenthal, Uniklinik RWTH Aachen and RTWH Aachen University collaborate to advance pain research

Aachen (ots) - Grünenthal, Uniklinik RWTH Aachen and RWTH Aachen University announced a collaboration to advance the development of next-generation pain medicines. The collaboration involves the institutes of Dr Angelika Lampert, Professor of Physiology at the Uniklinik RWTH Aachen and Dr Marc Spehr, ...

Neuromod Devices Ltd

Neuromod Publishes Results of Second Large Scale Clinical Trial for Tinnitus in Top-Tier Scientific Journal, Shows Greater Improvement of Symptoms

Dublin (ots/PRNewswire) - - Second large-scale trial shows greater reduction in tinnitus symptom severity using bimodal neuromodulation device, Lenire® - 91% of treatment compliant participants experienced improvement in tinnitus symptoms that sustained 12 months after treatment - 87.8% said they would recommend ...

News Direct

UK MEDTECH COMPANY TO HELP PROTECT US HEALTHCARE WORKERS AND US CITIZENS FROM 1 MILLON NEEDLESTICK INJURIES EACH YEAR

Liverpool England and Philadelphia USA (ots) - --News Direct-- SAFETY INITIATIVE AND COMPLIANCE WILL SAVE AMERICAN HEALTHCARE INDUSTRY $1 BILLION British smart MedTech company NeedleSmart, which is pioneering disruptive technologies in the global healthcare sector, is expanding into the US healthcare market to ...

MC2 Therapeutics

Professor Lars Iversen joins MC2 Therapeutics as new Chief Medical Officer

Copenhagen (ots/PRNewswire) - MC2 Therapeutics A/S, a commercial stage pharmaceutical company, has named Lars Iversen, MD, DMSc an esteemed chair professor in dermatology at Aarhus University Hospital and at Aarhus University, its new full-time Chief Medical Officer (CMO) as of October 1st, 2022. Professor Lars Iversen will be a key member of the Executive Team at MC2 ...

Medison Pharma

Medison Pharma Announces the Approvals by Health Canada and Therapeutics Goods Administration of KIMMTRAK® (tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma

Petach Tikvah, Israel (ots/PRNewswire) - KIMMTRAK has been approved in Canada and Australia for the treatment of an aggressive form of ocular melanoma and follows approval in the United States and the European Union Today, Medison Pharma ("Medison"), a global pharma company focused on providing access to highly ...

Medison Pharma

Medison Pharma Announces Multi-Regional Partnership Agreement with argenx to Commercialize Efgartigimod Across Europe and Israel

Petach Tikvah, Israel (ots/PRNewswire) - Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, announced today an exclusive multi-regional agreement with argenx to commercialize efgartigimod in 14 countries, including ...

TauRx Pharmaceuticals Ltd

Tau-targeting Alzheimer's treatment, HMTM, moving toward regulatory submission based on initial data from TauRx's LUCIDITY trial

Singapore (ots/PRNewswire) - - LUCIDITY data suggest that participants receiving hydromethylthionine mesylate (HMTM) decline at a rate substantially less than is typical in Alzheimer's based on published research - Safety profile is favourable and consistent with previous HMTM studies - TauRx will now pursue ...

Oxitec

Oxitec and the Government of Djibouti Announce New Multi-Year Partnership to Fight Invasive Malaria-Transmitting Mosquitoes Threatening the Horn of Africa

Oxford, England (ots/PRNewswire) - - With strong support from the Government of Djibouti, this program will pilot a new Friendly™ mosquito control technology to combat the growing threat to the region posed by the rapidly spreading malaria vector, Anopheles stephensi. - Oxitec will work hand-in-hand with the ...

Schweizerischer Nationalfonds / Fonds national suisse

What triggers photoreceptor cell death in a disease leading to blindness?

Bern (ots) - In the common eye disease retinitis pigmentosa, the rods and cones of the retina slowly die. Single cell analysis provides insights into the onset of this process. First night blindness and tunnel vision, then the loss of contrast and colour and, in the worst case, total blindness: this is the typical course of retinitis pigmentosa, a hereditary disease of ...

Medison Pharma

Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New Zealand

Petach Tikvah, Israel (ots/PRNewswire) - The latest geographic growth increases Medison's global footprint across 25 countries in four continents, further strengthening its commercial offering Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients ...

POCARED Diagnostics; European Investment Bank

Pocared Diagnostics, an Israeli rapid infectious diseases diagnostics leader, secures a EUR 22 million EIB backing for completion of the development and commercialization of its rapid testing system

Rehovot, Israel (ots/PRNewswire) - - First EIB support for medtech investment in Israel - Financing to accelerate development of rapid testing system to improve infectious disease diagnosis and antibiotics stewardship - Automated phenotypic testing, revolutionizing infectious diseases diagnostics from sample to ...

Debiopharm International SA

Series A financing round lays foundation for international growth of digital cancer therapeutics Mika

Berlin/Lausanne/Barcelona/Munich (ots) - New investors with a successful track record in digital oncology support German Digital Therapeutics (DTx) company Fosanis to broaden patient access of Mika - an app-based DTx platform empowering people affected by cancer. Berlin-based digital health company Fosanis, the ...